Ponatinib with Fludarabine, Cytarabine, Idarubicin, and Granulocyte Colony-Stimulating Factor Chemotherapy for Patients with Blast-Phase Chronic Myeloid Leukaemia (MATCHPOINT): a Single-Arm, Multicentre, Phase 1/2 Trial
The Lancet Haematology（2022）
关键词
Treatment Outcomes
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要